RxDoctor Payments Data

Meredith Blackburn, PA

Physician Assistant · Rochester, NYNPI 1558079624

Payments from drug & device makers

$568in general payments, 2019–2025

Across 20 payments — averaging $28.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$169
  • Johnson & Johnson$159
  • AstraZeneca$59
  • Bristol Myers Squibb$50
  • Merck$45
  • Takeda Pharmaceuticals U.S.A., Inc.$23
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$39970%
  • Education$16930%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$568 in reported general payments places this provider in the 65th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$17,131
Medicare patients
100
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib25$327,916
RevlimidLenalidomide14$286,218
XtandiEnzalutamide24$265,523
IbrancePalbociclib16$239,348
KisqaliRibociclib Succinate11$166,977
StivargaRegorafenib13$151,996
Abiraterone Acetate40$151,134
LonsurfTrifluridine/Tipiracil Hcl13$89,631
EliquisApixaban30$34,087
XareltoRivaroxaban29$31,905
OrgovyxRelugolix12$28,463
Imatinib Mesylate21$23,431
CreonLipase/Protease/Amylase11$17,476
AranespDarbepoetin Alfa In Polysorbat12$10,268
Aprepitant12$1,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$50$286,21814 claims
Astellas Pharma US IncXtandi$169$265,52324 claims
NovartisKisqali$22$166,97711 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$20$151,13440 claims
Johnson & JohnsonXarelto$159$31,90529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →